In-Person + Virtual

Medical Crossfire®: Matching the Targeted Therapy to the Mutation in EGFR-Mutated Metastatic NSCLC

November 21, 2026Ritz Carlton1 Miramontes Point Rd, Half Moon Bay, CA 94019

Countdown to Event

00

Days

00

Hours

00

Mins

00

Secs

Overview:

Treating patients with EGFR-mutated metastatic NSCLC is no longer one treatment decision. Classical mutations now carry a first-line choice between a third-generation EGFR tyrosine kinase inhibitor alone and two intensified regimens. Exon 20 insertions have an approved infused first-line standard and oral regimens with new phase 3 data, while atypical and compound variants are matched to agents largely on single-arm evidence. Each class presents its own decision tree, requiring careful consideration of clinical data and patient/disease characteristics.

The Medical Crossfire® format puts these unsettled decisions before a faculty panel that takes positions and defends them with evidence. This program will convene national thoracic oncology leaders, the clinicians who set institutional practice and train others, and the livestream will carry the debate to the greater thoracic oncology community.

Learning Objectives:

Upon completion of this activity, participants will be able to:

  • Evaluate phase 3 evidence for first-line TKI monotherapy, TKI-chemotherapy and bispecific antibody-TKI combinations to identify patients with classical EGFR-mutated metastatic NSCLC who benefit from intensification
  • Compare approved and emerging oral TKI and bispecific antibody strategies for EGFR exon 20 insertion-mutated NSCLC across lines of therapy, including differences in dosing and toxicity
  • Develop first-line treatment plans for atypical and compound EGFR mutations based on the structural class of the reported variant, CNS disease, and the strength of evidence

        Target Audience:

        This educational activity is directed toward medical oncologists, thoracic oncologists, pathologists, advanced practice providers, nurses, pharmacists, and other health care professionals involved in the care of patients with EGFR-mutant non-small cell lung cancer.

        Ready to attend?

        Secure your spot at Medical Crossfire®: Matching the Targeted Therapy to the Mutation in EGFR-Mutated Metastatic NSCLC.